Clinical trials: HER2 + Gastric Cancer
Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancer
- Trial name
- NCT04309578
- Testing
- Trastuzumab, Capecitabine and Cisplatin
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Asan Medical Center
HER2-positive Gastric Cancer
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive…
- Trial name
- NCT07332533
- Testing
- KN026, Capecitabine, Enlonstobart
- Volunteers
- 490 people
- Sponsor
- Shanghai JMT-Bio Inc.
MSI-H Colorectal Cancer, Melanoma
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.
- Conditions
- MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma
- Trial name
- ACROPOLI (NCT04802876)
- Testing
- Spartalizumab, Tislelizumab
- Where
- Spain
- Volunteers
- 184 people
- Sponsor
- SOLTI Breast Cancer Research Group
Gastric Cancer
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
This is a phase II, one-arm study, which is aiming to evaluate the feasibility of combination of Disitamab Vedotin, Sintilimab and S-1 as conversion therapy in patients with HER2 overexpression unresectable gastric cancer .
- Trial name
- NCT05627414
- Testing
- Disitamab Vedotin, Sintilimab, S-1
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
GastroEsophageal Cancer
Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
Combining Erb inhibitors, such lapatinib, and TS inhibitors, such as capecitabine, may be a beneficial contribution to current treatment paradigms since preclinical data suggest that lapatinib alone can decrease TS mRNA and is…
- Trial name
- GastroLap (NCT01145404)
- Testing
- Lapatinib, Lapatinib plus capecitabine
- Where
- 16 sites in Germany
- Volunteers
- 76 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
HER-2 Positive Gastric Cancer, Metastatic Cancer
Herzuma-capecitabine/Cisplatin for Gastric Cancer
Stomach cancer is the fifth largest cancer in the world. Despite many combinations of studies, metastatic stomach cancer shows a median survival period of 10 to 12 months.
- Trial name
- HERZUMA-GC (NCT03588533)
- Testing
- Trastuzumab, Capecitabine, Cisplatin
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Sung Yong Oh
HER2-negative Breast Cancer, Gastric Adenocarcinoma
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Homologous Recombination Repair (HRR) gene mutations can be detected in many solid tumors, patients with HRR gene mutations may benefit from PARP inhibitor.
- Conditions
- HER2-negative Breast Cancer, Gastric Adenocarcinoma, Cholangiocarcinoma, Pancreatic Cancer
- Trial name
- NCT04764084
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University Cancer Hospital & Institute
Gastric Carcinoma
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX as first-line treatment for patients with HER2-low advanced…
- Trial name
- NCT06944496
- Testing
- Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine
- Where
- China
- Volunteers
- 616 people
- Sponsor
- RemeGen Co., Ltd.
HER2 Negative Gastric Cancer
Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma
The purpose of the study is to compare efficacy and safety of palliative chemotherapy EOX and mDCF regimens in the first-line treatment of patients with advanced HER2-negative gastric and gastroesophageal junction (GEJ)…
- Trial name
- NCT02445209
- Testing
- EOX, mDCF
- Volunteers
- 56 people
- Sponsor
- Jagiellonian University
Gastric Cancer
Observational Study of Perioperative Chemotherapy in Gastric Cancer
This study will assess the efficacy and toxicity of perioperative chemotherapy with Epirubicin + Cisplatin + Capecitabine (ECX) in routine clinical practice in a network of public hospitals in Santiago, Chile.
- Trial name
- PRECISO (NCT01633203)
- Testing
- epirubicin + cisplatin + capecitabine polychemotherapy
- Where
- Chile
- Volunteers
- 61 people
- Sponsor
- Grupo Oncologico Cooperativo Chileno de Investigation
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for…
- Trial name
- NCT03929666
- Testing
- ZW25 (Zanidatamab), Capecitabine, Cisplatin
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 74 people
- Sponsor
- Jazz Pharmaceuticals
Breast Cancer, Gastric Cancer
IKS014 in Advanced Solid Tumors That Express HER2
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT05872295
- Testing
- IKS014
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 165 people
- Sponsor
- Iksuda Therapeutics Ltd.
Stomach Neoplasms, Solid Tumor
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
The safety, tolerability, and determination of the maximum tolerated dose (MTD) of the combination therapy were first evaluated for IAH0968 in combination with or without the CAPEOX regimen in unsystematically treated subjects…
- Trial name
- NCT06504732
- Testing
- IAH0968, Trastuzumab Injection
- Where
- 2 sites in China
- Volunteers
- 574 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
This Phase 1b trial is an open label, multi-center study of XMT-1522 administered as an intravenous infusion once every three weeks.
- Conditions
- Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer, Advanced Gastric Cancer
- Trial name
- NCT02952729
- Testing
- XMT-1522
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Mersana Therapeutics
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
HER 2 Positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
The study will have a dose escalation part (Phase 1b) and a randomized part (Phase 2). In Phase 1b, patients diagnosed with advanced HER2 positive gastric/gastroesophageal adenocarcinoma will be enrolled in a 3 + 3 design dose…
- Trial name
- NCT07040059
- Testing
- AUR103 Calcium, Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)
- Where
- 8 sites in India
- Volunteers
- 2 people
- Sponsor
- Aurigene Discovery Technologies Limited
HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
TAC T-cells for the Treatment of HER2-positive Solid Tumors
TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
- Trial name
- TACTIC-2 (NCT04727151)
- Testing
- TAC01-HER2, TAC01-HER2 plus pembrolizumab
- Where
- 11 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Triumvira Immunologics, Inc.
Gastric Cancer
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
This is a randomized, controlled, multicenter phase Ⅲ study to evaluate the therapeutic efficacy of modified XELOX plus sintilimab versus standard XELOX plus sintilimab in subjects with advanced HER2-negative gastric or…
- Trial name
- NCT05918094
- Testing
- Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab
- Where
- 10 sites in China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Male Breast Cancer, Recurrent Breast Cancer
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in treating patients who have solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer
- Trial name
- NCT00028535
- Testing
- trastuzumab, paclitaxel, recombinant interleukin-12
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)